GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...

Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...

GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...

Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed it is shutting one of its UK factories in June 2025. The site in Ulverston, Cumbria, has been producing the antibiotic Zinnat for the Swiss ...

Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed job losses at one of its UK sites. It is believed about 200 roles will be cut at the facility in Barnard Castle, County Durham, in October 2025.

This report presents key facts and figures about the British pharmaceutical company GSK, formerly known as GlaxoSmithKline. GSK is one of the world's 10 largest pharmaceutical companies.